Microba Life Sciences (ASX:MAP) Other Long-Term Liabilities: A$0.98 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Microba Life Sciences Other Long-Term Liabilities?

Microba Life Sciences ASX:MAP -1.72% Other Long-Term Liabilities is A$0.98 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.98 Mil.

Microba Life Sciences's quarterly other long-term liabilities increased from Dec. 2024 (A$0.59 Mil) to Jun. 2025 (A$0.98 Mil) but then declined from Jun. 2025 (A$0.98 Mil) to Dec. 2025 (A$0.98 Mil).

Microba Life Sciences's annual other long-term liabilities increased from Jun. 2023 (A$0.15 Mil) to Jun. 2024 (A$2.29 Mil) but then declined from Jun. 2024 (A$2.29 Mil) to Jun. 2025 (A$0.98 Mil).

Microba Life Sciences Other Long-Term Liabilities Related Terms

Microba Life Sciences Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Other Long-Term Liabilities Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
0.10 0.15 2.29 0.98

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only 2.49 2.29 0.59 0.98 0.98

Microba Life Sciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.98 Mil mean?
Microba Life Sciences (ASX:MAP) has a Other Long-Term Liabilities of A$0.98 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Other Long-Term Liabilities too high?
Microba Life Sciences' current Other Long-Term Liabilities is A$0.98 Mil.
How does Microba Life Sciences' Other Long-Term Liabilities compare to TMO and DHR?
Microba Life Sciences' Other Long-Term Liabilities of A$0.98 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Other Long-Term Liabilities is A$0.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.24, compared to a current price of A$0.06 — trading 76.3% below its estimated fair value. The current Other Long-Term Liabilities is A$0.98 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Other Long-Term Liabilities is A$0.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.